Business Description
BriaCell Therapeutics Corp
NAICS : 325414
SIC : 3741
ISIN : CA10778Y1043
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | -0.96 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 38.9 | |||||
3-Year EPS without NRI Growth Rate | 37 | |||||
3-Year FCF Growth Rate | 5.7 | |||||
3-Year Book Growth Rate | 64.1 | |||||
Future 3-5Y EPS without NRI Growth Rate | 33.22 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 49.21 | |||||
9-Day RSI | 54.3 | |||||
14-Day RSI | 55.08 | |||||
6-1 Month Momentum % | -76.8 | |||||
12-1 Month Momentum % | -88.78 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.82 | |||||
Quick Ratio | 0.82 | |||||
Cash Ratio | 0.14 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -180.8 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROA % | -30.78 | |||||
ROIC % | -1610.12 | |||||
ROC (Joel Greenblatt) % | -1062.01 | |||||
ROCE % | -205.88 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
EV-to-EBIT | -1.02 | |||||
EV-to-Forward-EBIT | -0.77 | |||||
EV-to-EBITDA | -1.02 | |||||
EV-to-FCF | -1.24 | |||||
Earnings Yield (Greenblatt) % | -98.39 | |||||
FCF Yield % | -90.98 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
BriaCell Therapeutics Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil C$) | |||
EPS (TTM) (C$) | -1.687 | ||
Beta | 2.04 | ||
Volatility % | 93.49 | ||
14-Day RSI | 55.08 | ||
14-Day ATR (C$) | 0.24227 | ||
20-Day SMA (C$) | 1.054 | ||
12-1 Month Momentum % | -88.78 | ||
52-Week Range (C$) | 0.64 - 8 | ||
Shares Outstanding (Mil) | 35.84 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
BriaCell Therapeutics Corp Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
BriaCell Therapeutics Corp Stock Events
Event | Date | Price(C$) | ||
---|---|---|---|---|
No Event Data |
BriaCell Therapeutics Corp Frequently Asked Questions
What is BriaCell Therapeutics Corp(TSX:BCT)'s stock price today?
When is next earnings date of BriaCell Therapeutics Corp(TSX:BCT)?
Does BriaCell Therapeutics Corp(TSX:BCT) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |